In agreement with our findings, the Tamoxifen Chemoprevention Trial [31] showed reduction of breast-cancer risk only for ER-positive tumors, further supporting the fundamental specificity of the in vivo ligand-estrogen receptor effects. The gene discussed is ESR1; the disease is breast carcinoma.